Saby George, MD
Enriched profileProfessor of Oncology, Department of Medicine, and Director of Network Clinical Trials at Roswell Park Comprehensive Cancer Center · Roswell Park Comprehensive Cancer Center
Saby George is Professor of Oncology, Department of Medicine, and Director of Network Clinical Trials at Roswell Park Comprehensive Cancer Center at Roswell Park Comprehensive Cancer Center. OpenAlex indexes 323 publications with 22,167 citations (h-index 46); ClinicalTrials.gov lists 12 registered studies with this person as an investigator.
Data verified 17 Oct 2026
Overview
Updated 18 Oct 2026
Saby George, MD, is Professor of Oncology, Department of Medicine, and Director of Network Clinical Trials at Roswell Park Comprehensive Cancer Center. The public record shows 323 publications with 22,167 citations (h-index 46), centered on Cancer Immunotherapy and Biomarkers, Renal cell carcinoma treatment, Bladder and Urothelial Cancer Treatments. It also documents an investigator role on 12 registered clinical trials, industry payments reported by 22 companies.
- Most recent indexed publication: 2025 · JCO oncology practice
- Top research focus: Cancer Immunotherapy and Biomarkers
- 12 registered trials on ClinicalTrials.gov
- Open Payments reporting from 22 companies
Generated from the cited public record · current as of 18 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 8 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 120.
Clinical & industry
trials, payments and federal fundingFederally funded research awards.
Contact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 18 Oct 2026
Listed as an investigator on 12 registered studies on ClinicalTrials.gov. The most recent:
- Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer
Sponsor: Alliance for Clinical Trials in Oncology
- Bipolar Androgen Therapy to Restore Sensitivity to Androgen Deprivation Therapy for Patients With Metastatic Castration Resistant Prostate Cancer
Sponsor: Roswell Park Cancer Institute
Industry payments
Updated 18 Oct 2026
22 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Exelixis Inc.Program year202516 payments
- AstraZeneca Pharmaceuticals LPProgram year20257 payments
- Eisai Inc.Program year20253 payments
Medicare prescribing footprint (2022)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
100%Calcium channel blocker100%Amlodipine Besylate100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →
Congress activity
Updated 18 Oct 2026
115 congress contributions (2007–2026) across AACR, ASCO, ASTRO, ESMO per OpenAlex. The most recent:
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 18 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of AGS15E Monotherapy in Patients with Metastatic Urothelial Carcinoma.
Clinical cancer research
Clinical Trial2024 - Enfortumab Vedotin With or Without Pembrolizumab in Cisplatin-Ineligible Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer.
Journal of clinical oncology
Clinical Trial2023
Most-cited works
by citation count (OpenAlex)- 01Nivolumab versus Everolimus in Advanced Renal-Cell CarcinomaArticle5,797 citations2015
- 02Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell CarcinomaArticle4,637 citations2018
- 03Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II TrialArticle1,074 citations2014
- 04
- 05Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in OncologyArticle667 citations2022
Network
Updated 18 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 18 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/saby-george-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗
Mentions by others
where others cite or feature them- Other
themedicinementors.libsyn.com/2024/01
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →themedicinementors.libsyn.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 18 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- MD from Kottayam Medical College
Kerala, India
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →roswellpark.org ↗
Editorial & leadership roles
journal and society appointments- Director of Network Clinical Trials
Department of Medicine
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →roswellpark.org ↗
Awards & honors
honors on the public record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →roswellpark.org ↗
Secondary affiliations
appointments beyond the home institution- Jacobs School of Medicine and Biomedical Sciences
University at Buffalo
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →roswellpark.org ↗
Media & interviews
press, podcasts and appearances- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cancerresearch.org ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Philip McCarthy, MD
Roswell Park Comprehensive Cancer Center
Eunice Wang, MD
Roswell Park Comprehensive Cancer Center
Renuka Iyer, MD
Roswell Park Comprehensive Cancer Center
Ellis Levine, MD
Roswell Park Comprehensive Cancer Center
Howard Scher, MD
Memorial Sloan Kettering Cancer Center
Toni Choueiri, MD
Dana-Farber Cancer Institute
Robert Motzer, MD
Memorial Sloan Kettering Cancer Center
Fred Saad, MD
Centre hospitalier de l'Université de Montréal (CHUM)